Gaorong Capital partner: AI drug discovery still at 0-to-1 stage, bet on long boards

创业邦 · wechat · 2026-11-21

Gaorong Capital managing director Le Beilin shared his biotech investment playbook at DEMOCHINA 2026, drawing on cases like Protoby (acquired by Genmab for $1.8B) and Cotounsel (7B?) — actually a $700M strategic partnership with Medtronic.

Key points:

On the BD licensing wave, he sees value but warns against one-off "fire sales" that drain China's innovative assets. Companies that survive cycles share continuous team learning, strong cash reserves (70-80% of failed deals died from cash problems), and openness to talent.

Original post →

More from Companies & People

Companies & People channel →